Arctic Aurora LifeScience A SEKRegister to Unlock Ratings |
Performance History | 31/08/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 10.5 | 3.9 | 7.1 | 2.4 | 16.3 | |
+/-Cat | -6.9 | -5.6 | 11.7 | 5.6 | 8.8 | |
+/-B’mrk | - | -14.3 | 1.2 | 5.0 | 2.8 | |
Category: Sector Equity Healthcare | ||||||
Category Benchmark: Morningstar Gbl Health TME ... |
Key Stats | ||
NAV 25/09/2024 | SEK 1717.79 | |
Day Change | 0.32% | |
Morningstar Category™ | Sector Equity Healthcare | |
ISIN | IE00BJRFW715 | |
Fund Size (Mil) 31/08/2024 | NOK 2654.99 | |
Share Class Size (Mil) 31/08/2024 | SEK 12.00 | |
Max Initial Charge | - | |
Ongoing Charge 29/12/2023 | 2.15% |
Investment Objective: Arctic Aurora LifeScience A SEK |
The investment objective is to achieve long-term capital appreciation through global equity investments within the pharmaceuticals, biotechnology and life science sectors. The team has more than 50 years of experience from the industry, and will utilize their know-how to pick the early winners in a fast developing life science and biotech space. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Ulrica Bjerke 27/05/2016 | ||
Daniel Bolanowski 01/06/2021 | ||
Inception Date 02/10/2019 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI World/Pharma Bio&Life NR NOK | Morningstar Gbl Health TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Arctic Aurora LifeScience A SEK | 31/07/2024 |
|
|
Top 5 Holdings | Sector | % |
Eli Lilly and Co | Healthcare | 8.26 |
Novo Nordisk A/S Class B | Healthcare | 7.39 |
AstraZeneca PLC | Healthcare | 5.89 |
Merck & Co Inc | Healthcare | 3.52 |
Daiichi Sankyo Co Ltd ADR | Healthcare | 3.01 |
Increase Decrease New since last portfolio | ||
Arctic Aurora LifeScience A SEK |